drugset / Trial / NCT00230763

Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure

NCT00230763

Phase 3 Completed 396 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's medical history, family history of OAG or OHT, concomitant systemic treatment with beta-blockers, etiology, IOP at baseline, corneal thickness, compliance, and adverse events).

Timeline

Start
2005-09
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 %
Subject Timolol Other / unclassified 0.5 %